Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on oncology, has announced new hiring incentives. The Compensation Committee of the Company’s Board of Directors has Three new employees have the option to purchase 21,100 shares At the exercise price of the common stock $18.01 per sharewhich was the closing price on August 23, 2024. Furthermore, Restricted stock units acquire 10,550 shares These stock awards are made in the form of shares of the Company’s common stock. 2020 Attraction PlanApproved by the Board of Directors in January 2020 pursuant to the “Inducement Exception” to Rule 303A.08 of the NYSE Listed Company Manual.
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on oncology, has announced new hiring incentives. Approved by the Compensation Committee of the Company’s Board of Directors Option to purchase 21,100 shares Normal $18.01 per sharewhich was the closing price on August 23, 2024. Moreover, they were granted. Acquire 10,550 restricted stock units Ordinary. These stock awards are: 2020 Incentive Planwhich was approved by our Board of Directors in January 2020 pursuant to the “Incentive Exception” to Rule 303A.08 of the NYSE Listed Company Manual.
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on oncology, has announced new service incentive awards. The Compensation Committee of the Company’s Board of Directors has Options to purchase 21,100 shares Common stock exercise price $18.01 per sharewhich is the closing price on August 23, 2024. Also, Acquire 10,550 restricted stock units These stock awards were issued under: 2020 Incentive Planwhich was approved by our Board of Directors in January 2020 pursuant to the “Incentive Exception” to Rule 303A.08 of the NYSE Listed Company Manual.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biotechnology company focused on cancer therapeutics, has announced new employment incentive compensation offers. The Compensation Committee of the Company’s Board of Directors has 21,100 per week for 3 new employeesOptions to purchase common stock $18.01 per weekThe shares were granted at the event price of , which was the closing price on August 23, 2024. Limited stock units to acquire 10,550 common sharesThese capital bonuses were 2020 manned mission planwhich corresponds to the “attached exception” to Rule 303A.08 in the NYSE Listed Company Manual approved by the Board of Directors in January 2020.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on oncology, has announced new hiring incentives. The three new employees will be given the option to purchase 21,100 shares. Common stock exercise price $18.01 per sharewhich is the closing price on August 23, 2024. Furthermore, Acquire 10,550 restricted stock units These stock grants were given to 2020 Incentive Planwhich was approved by our Board of Directors in January 2020 pursuant to the “Incentive Exception” to Rule 303A.08 of the NYSE Listed Company Manual.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on oncology, has announced new hiring incentive awards. The Compensation Committee of the company’s board of directors has 21,100 stock purchase options for three new employees At the strike price of $18.01 per share This corresponds to the closing price on August 23, 2024. Restricted stock units to purchase 10,550 shares The payment for these shares was 2020 Incentive Plan This was approved by our Board of Directors in January 2020 pursuant to the “Incentive Exemption” to Rule 303A.08 of the NYSE Listing Rules.
positive
- Arcus Biosciences Attracts New Talent with Equity Incentives
- The company is offering a competitive compensation package through its 2020 incentive plan.
About Arcus Biosciences
Arcus Biosciences is a global clinical-stage biopharmaceutical company developing differentiated molecules and combinations for patients with cancer. Arcus partners with industry collaborators, patients and physicians around the world to accelerate the development of first-in-class or best-in-class drugs against well-characterized biological targets and pathways, and to investigate novel biology-driven combinations that may help extend the lives of cancer patients. Founded in 2015, the company has rapidly advanced the development of multiple investigational agents into clinical studies, including novel combination approaches targeting TIGIT, PD-1, adenosine axis (CD73 and dual A2a/A2b receptors), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Induced PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826881267/ja/
Investor Inquiries:
Pierre Eaves
Vice President, Investor Relations and Strategy
(617) 459-2006
inquiry
For media enquiries please contact:
Holly Corky
Vice President, Corporate Communications
(650) 922-1269
inquiry
Source: Arcus Biosciences
FAQ
What stock options did Arcus Biosciences (RCUS) grant to new employees?
Arcus Biosciences has granted the three new employees options to purchase a total of 21,100 shares of the company’s common stock at an exercise price of $18.01 per share.
How many restricted stock units did Arcus Biosciences (RCUS) grant in its recent announcement?
Arcus Biosciences has granted restricted stock units to acquire a total of 10,550 shares of the company’s common stock.
What was the exercise price of the stock options granted by Arcus Biosciences (RCUS) on August 23, 2024?
The exercise price of the stock options granted was $18.01 per share, which was the closing price on August 23, 2024.
Under what plan were Arcus Biosciences (RCUS) stock awards granted?
The stock awards were granted pursuant to Arcus Biosciences’ 2020 Incentive Plan, which was approved by the company’s board of directors in January 2020.
#Arcus #Biosciences #Announces #Job #Incentive #Grants #RCUS #Stock #News